Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 43.48 percent increase over losses of $(0.23) per share
